Ribaldone D G, Dileo I, Pellicano R, Resegotti A, Fagoonee S, Vernero M, Saracco G, Astegiano M
Gastroenterology-U, General and Specialist Medicine Department, Città della Salute e della Scienza of Turin, C.so Bramante 88, 10126, Turin, Italy.
Department of Gastroenterology and Hepatology, Molinette Hospital-S.G.A.S, Via Cavour 31, 10123, Turin, Italy.
Ir J Med Sci. 2018 May;187(2):385-392. doi: 10.1007/s11845-017-1666-0. Epub 2017 Jul 29.
There is no agreeing if rescue therapy can avoid short-term colectomy in patients treated for severe steroid-refractory ulcerative colitis.
The aim of our study was to identify predictors of response to infliximab and cyclosporine A.
In this cross-sectional study, 49 patients with severe ulcerative colitis were included. Response to therapy was defined as three or more point reductions in Mayo score after 6 months of treatment and avoidance of colectomy after 1 year. The predictors analysed were gender, age, time from ulcerative colitis diagnosis, months of steroid or/and azathioprine therapy before onset of the severe phase, smoking habits, extension of the disease, laboratory analyses and Mayo score.
Patients treated with infliximab showed a statistically significant higher response rate in case of moderate Mayo score (P = 0.04). Ex-smokers had very low chance of response to infliximab (P = 0.03). In the group treated with cyclosporine A, patients with C-reactive protein >3 mg/L had a response rate significantly higher than those with C-reactive protein <3 mg/L (P = 0.03); those with negative C-reactive protein and moderate Mayo score did not responded to therapy, while in the ones with elevated C-reactive protein and/or severe Mayo score, 15 versus 4 responded (P = 0.008).
Our data suggest that cyclosporine A is advisable in ex-smokers. In never smokers or active smokers, infliximab can be prescribed in case of Mayo score ≤10 and/or negative CRP, while cyclosporine A is indicated in case of Mayo score >10 and positive CRP.
对于接受治疗的严重激素难治性溃疡性结肠炎患者,挽救疗法能否避免短期结肠切除术尚无定论。
我们研究的目的是确定英夫利昔单抗和环孢素A反应的预测因素。
在这项横断面研究中,纳入了49例严重溃疡性结肠炎患者。治疗反应定义为治疗6个月后梅奥评分降低3分或更多,以及1年后避免结肠切除术。分析的预测因素包括性别、年龄、自溃疡性结肠炎诊断以来的时间、严重期开始前使用激素或/和硫唑嘌呤治疗的月数、吸烟习惯、疾病范围、实验室分析和梅奥评分。
在梅奥评分中等的情况下,接受英夫利昔单抗治疗的患者显示出统计学上显著更高的反应率(P = 0.04)。既往吸烟者对英夫利昔单抗的反应机会非常低(P = 0.03)。在接受环孢素A治疗的组中,C反应蛋白>3 mg/L的患者反应率显著高于C反应蛋白<3 mg/L的患者(P = 0.03);C反应蛋白阴性且梅奥评分中等的患者对治疗无反应,而C反应蛋白升高和/或梅奥评分严重的患者中,15例有反应,4例无反应(P = 0.008)。
我们的数据表明,环孢素A对既往吸烟者是可取的。对于从不吸烟者或现吸烟者,梅奥评分≤10和/或C反应蛋白阴性时可开具英夫利昔单抗,而梅奥评分>10和C反应蛋白阳性时则应使用环孢素A。